ARS Pharmaceuticals (NASDAQ:SPRY) is gearing up to announce its quarterly earnings on Monday, 2026-03-09. Here's a quick overview of what investors should know before the release.

Analysts are estimating that ARS Pharmaceuticals will report an earnings per share (EPS) of $-0.46.

ARS Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings History Snapshot

During the last quarter, the company reported an EPS missed by $0.05, leading to a 1.24% drop in the share price on the subsequent day.

Here's a look at ARS Pharmaceuticals's past performance and the resulting price change:

Performance of ARS Pharmaceuticals Shares

Shares of ARS Pharmaceuticals were trading at $9.12 as of March 05. Over the last 52-week period, shares are down 15.79%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Delving into ARS Pharmaceuticals's Background

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Unraveling the Financial Story of ARS Pharmaceuticals

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Positive Revenue Trend: Examining ARS Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1471.62% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: ARS Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -157.38%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): ARS Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -30.09%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): ARS Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.91%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: ARS Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 0.66. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

To track all earnings releases for ARS Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.